Pegcetacoplan as a targeted C3 inhibitor in C3 glomerulopathy and immune-complex MPGN
Open Access
- 30 June 2026
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5524-5525
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGNNew England Journal of Medicine, 2025
- Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGNNew England Journal of Medicine, 2025
- Transparency in the Reporting of Artificial Intelligence – The TITAN GuidelinePremier Journal of Science, 2025
- The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2024
- Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safetyResearch and Practice in Thrombosis and Haemostasis, 2022
- Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the DiseaseClinical Journal of the American Society of Nephrology, 2020
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationOphthalmology, 2020
- Patterns of Clinical Response to Eculizumab in Patients With C3 GlomerulopathyAmerican Journal of Kidney Diseases, 2018
- Membranoproliferative Glomerulonephritis — A New Look at an Old EntityNew England Journal of Medicine, 2012